^
Association details:
| Biomarker: | TP53 mutation + ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
Published date:
07/11/2023
Excerpt:
The phase 2, single-arm, multicenter, open-label J-ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non-small-cell lung cancer (NSCLC).....Patients with a TP53 mutation had significantly shorter PFS (median, 1.8 months) than patients with TP53 WT (median, 9.3 months; HR, TP53 mutation versus WT: 4.9 [95% CI, 3.7–6.5]; p < 0.0001; Figure 4B) and shorter DoR (median, 4.8 months) than patients with TP53 WT (median, 16.4 months; HR: 5.7 [1.8–18.6]; p = 0.01).
DOI:
https://doi.org/10.1111/cas.15888
Trial ID:
